Ying Wang1, Eric J Jacobs2, Brian D Carter2, Susan M Gapstur2, Victoria L Stevens2. 1. Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA. Electronic address: ying.wang@cancer.org. 2. Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA.
Abstract
BACKGROUND: Little is known about the underlying molecular mechanisms of prostate cancer, especially advanced and fatal prostate cancer. OBJECTIVE: To examine associations of prediagnostic plasma metabolomic profiles with advanced and fatal prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: In a case-cohort study of the Cancer Prevention Study-II Nutrition Cohort, of 14 210 cancer-free men with a blood sample in 1998-2001, 129 were diagnosed with advanced prostate cancer (T3-T4 or N1 or M1) through June 2013 and 112 died from prostate cancer through December 2014. Plasma samples from advanced and fatal cases, and a randomly selected subcohort of 347 men were metabolically profiled using untargeted mass spectroscopy-based platforms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prentice-weighted Cox proportional hazards regression models were used to assess associations of 699 known metabolites with advanced and fatal prostate cancer. RESULTS AND LIMITATIONS: Two metabolites derived from fatty acid metabolism (ethylmalonate and butyrylcarnitine), aspartate, sphingomyelin (d18:1/18:0), and two γ-glutamyl amino acids (γ-glutamylmethionine and γ-glutamylglutamine) were statistically significantly associated (false discovery rate <0.2) with fatal prostate cancer. One standard deviation (SD) increase in each γ-glutamyl amino acid was associated with 34-38% decreased risk, whereas one SD increase in each of the other metabolites was associated with 45-53% increased risk. A metabolic risk score based on four of these metabolites (excluding butyrylcarnitine and γ-glutamylglutamine, which were not independent predictors) was strongly associated with fatal prostate cancer (relative risk per SD: 2.72, 95% confidence interval: 2.05-3.60). No metabolites were statistically significantly associated with advanced prostate cancer. These results were observational and may not be causal. CONCLUSIONS: These findings identified metabolic pathways that are altered in the development of fatal prostate cancer. Further research into these pathways may provide insights into the etiology of fatal prostate cancer. PATIENT SUMMARY: In a large follow-up study of cancer-free men, those with a certain metabolomic profile had a higher risk of dying from prostate cancer.
BACKGROUND: Little is known about the underlying molecular mechanisms of prostate cancer, especially advanced and fatal prostate cancer. OBJECTIVE: To examine associations of prediagnostic plasma metabolomic profiles with advanced and fatal prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: In a case-cohort study of the Cancer Prevention Study-II Nutrition Cohort, of 14 210 cancer-free men with a blood sample in 1998-2001, 129 were diagnosed with advanced prostate cancer (T3-T4 or N1 or M1) through June 2013 and 112 died from prostate cancer through December 2014. Plasma samples from advanced and fatal cases, and a randomly selected subcohort of 347 men were metabolically profiled using untargeted mass spectroscopy-based platforms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prentice-weighted Cox proportional hazards regression models were used to assess associations of 699 known metabolites with advanced and fatal prostate cancer. RESULTS AND LIMITATIONS: Two metabolites derived from fatty acid metabolism (ethylmalonate and butyrylcarnitine), aspartate, sphingomyelin (d18:1/18:0), and two γ-glutamyl amino acids (γ-glutamylmethionine and γ-glutamylglutamine) were statistically significantly associated (false discovery rate <0.2) with fatal prostate cancer. One standard deviation (SD) increase in each γ-glutamyl amino acid was associated with 34-38% decreased risk, whereas one SD increase in each of the other metabolites was associated with 45-53% increased risk. A metabolic risk score based on four of these metabolites (excluding butyrylcarnitine and γ-glutamylglutamine, which were not independent predictors) was strongly associated with fatal prostate cancer (relative risk per SD: 2.72, 95% confidence interval: 2.05-3.60). No metabolites were statistically significantly associated with advanced prostate cancer. These results were observational and may not be causal. CONCLUSIONS: These findings identified metabolic pathways that are altered in the development of fatal prostate cancer. Further research into these pathways may provide insights into the etiology of fatal prostate cancer. PATIENT SUMMARY: In a large follow-up study of cancer-free men, those with a certain metabolomic profile had a higher risk of dying from prostate cancer.
Authors: Oana A Zeleznik; Raji Balasubramanian; Yibai Zhao; Lisa Frueh; Sarah Jeanfavre; Julian Avila-Pacheco; Clary B Clish; Shelley S Tworoger; A Heather Eliassen Journal: NPJ Breast Cancer Date: 2021-05-18
Authors: Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Taofik Oyekunle; Gloria C G Alvarado; Adela Ramirez-Torres; Emily Y Chen; Valerie Bussberg; Bo Chi; Bennett Greenwood; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish; Stephen J Freedland Journal: Prostate Date: 2021-05-05 Impact factor: 4.012
Authors: Ericka M Ebot; Lorelei A Mucci; Xiaoshuang Feng; Cindy Ke Zhou; Clary B Clish; Kathryn M Wilson; Claire H Pernar; Barbra A Dickerman; Massimo Loda; Stephen P Finn; Kathryn L Penney; Daniel R Schmidt; Matthew G Vander Heiden; Edward L Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02-24 Impact factor: 4.090
Authors: Andrea C Pelosi; Anna Maria A P Fernandes; Leonardo F Maciel; Alex A R Silva; Giulia C Mendes; Luísa F Bueno; Lívia Maria F Silva; Rafael F Bredariol; Maycon G Santana; Andreia M Porcari; Denise G Priolli Journal: PLoS One Date: 2022-09-21 Impact factor: 3.752
Authors: Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Taofik Oyekunle; Emily Y Chen; Valerie Bussberg; Bennett Greenwood; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish; Stephen J Freedland Journal: Cancer Med Date: 2020-03-31 Impact factor: 4.452